Degenerative Arthritis Clinical Trial
Official title:
A Placebo Controlled, Single-blind, Randomized, Multi-center Phase 2B Study to Determine the Efficacy and Safety of TissueGene-C, an Allogeneic Human Chondrocytes Expressing TGF-b1, in Patients With Degenerative Arthritis
Verified date | January 2015 |
Source | Kolon Life Science |
Contact | n/a |
Is FDA regulated | No |
Health authority | Korea: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine whether TissueGene-C, an allogeneic human chondrocytes expressing Transforming Growth Factor(TGF)-b1, is effective and safe in patients with degenerative arthritis
Status | Completed |
Enrollment | 54 |
Est. completion date | January 2013 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Female or male aged 18 years or more 2. Diagnosed with degenerative arthritis of the knee 3. With an IKDC score of 60 or lower at the screening visit 4. With Grade 2 or 3 osteoarthritis as determined by the radiographic criteria of Kellgren and Lawrence 5. With a Body Mass Index(BMI) of higher than18.5 and lower than 30 6. With an International Cartilage Repair Society(ICRS) Grade IV cartilage damage in the major lesions, as confirmed through an MRI scan 7. With major lesions concentrated in one section of the knee, and with the major lesions considered the main cause of the clinical symptoms 8. With no alleviation of the symptoms even after at least three months of non-surgical treatment 9. Healthy, with no major findings from the physical examination, hematology, serum chemistry, and urine tests, and no significant medical history 10. Agreed to use an effective contraceptive method during the study period 11. Voluntarily agreed to participate in this study, and signed the informed consent form Exclusion Criteria: 1. Showed clinically significant hematology, serum chemistry, and urine test results at the screening visit 2. Falls under Inclusion Criteria 6 but with the damage in the relevant lesion considered ICRS Grade IV sized more than 6 cm2 3. Took glucosamine, chondroitin, or any natural medicine within 14 days before the injection of the investigational product (but if the 14-day washout period had elapsed, the patient can be enrolled in this study) 4. Has taken anti-inflammatory drugs (prescribed or over-the-counter) within 14 days before the injection of the investigational product (but if the 14-day washout period had elapsed, the patient can be enrolled in this study) 5. Has taken immunosuppressive agents, including antirheumatic drugs (e.g., methotrexate or antimetabolites) within 3 months before enrollment in this study 6. With a history of drug abuse within one year prior to enrollment in this study, or showed positive results in the urine drug test or the serum alcohol test at the screening visit 7. Received an injection in the target knee within two months before enrollment in this study 8. Pregnant or breastfeeding female 9. With another joint disease apart from degenerative arthritis (e.g., systemic rheumatic inflammatory disease associated with the knee or chondrocalcinosis, hemachromatosis, inflammatory arthritis, necrosis of the trochanter, Paget's disease adjacent to a joint in the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's disease in the knee joint, villonodular synovitis, synovial chondromas) 10. With an infectious disease, including HIV or hepatitis 11. With any of the following clinically significant diseases: - heart disease [e.g., myocardial infarction, arrhythmia, other serious heart diseases, coronary artery bypass graft (CABG)] - kidney disease (e.g., chronic renal failure, glomerulonephritis) - liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver disease) - endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes insipidus, Cushing's disease) - insulin-dependent diabetes mellitus - medical history of past or current malignant tumor - In particular, the tumors that TissueGene-C may aggravate can be screened using the following tests: - Leukemia (White Blood Cell level in the hematology) - Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma, Chondrosarcoma (Alkaline phosphatase level in the hematology) 12. Participated in another clinical trial (using the investigational drug or a medical device) within 30 days before enrollment in this study 13. Considered inappropriate by the investigator for participation in this study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Gangnam-gu | Seoul |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Seoul National Univ. Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Kolon Life Science |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in IKDC Subjective Score. | Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC) | Week 0 and 24 | No |
Secondary | Changes in WOMAC scores. | Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities (WOMAC) | Week 0 and 24 | No |
Secondary | Changes in KOOS scores. | Symptoms, pain and functionality of the knee joint will be evaluated via the Knee Injury and Osteoarthritis Outcome Score (KOOS) | Week 0 and 24 | No |
Secondary | Changes in 100 mm-VAS. | Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS) | Week 0 and 24 | No |
Secondary | MRI scan | Comparison of pre-procedure MRI scans to those obtained at pre-dosing and at months 6 and 12 following dosing by an independent radiographic reviewer. | Week 0 and 24 | Yes |
Secondary | Proportion of Patients Use of Rescue Medication | Week 4, 12 and 24 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02820766 -
Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting
|
N/A | |
Withdrawn |
NCT01308515 -
Vanguard Knee Anterior Stabilized Versus Posterior Stabilized Bearing Study
|
N/A | |
Terminated |
NCT03247023 -
Long Term Follow-up of Integra® Cadenceâ„¢ Total Ankle System in Primary Ankle Joint Replacement
|
||
Terminated |
NCT05357664 -
PINNACLE® DM RSA Study
|
N/A | |
Completed |
NCT01825811 -
Efficacy and Safety Study of TissueGene-C Mixed With Fibrin-glue for the Patients With Degenerative Arthritis
|
Phase 2 | |
Terminated |
NCT01366989 -
INBONE Total Ankle Arthroplasty(TAA)Using Calcaneal Stem Fixation
|
N/A | |
Not yet recruiting |
NCT02286973 -
Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty
|
Phase 1 | |
Completed |
NCT02072070 -
Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis
|
Phase 3 | |
Completed |
NCT01684371 -
The Effects of Elmore Oil on Patients With Osteoarthritis
|
N/A | |
Recruiting |
NCT00891501 -
The Use of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage Defects
|
Phase 2/Phase 3 | |
Completed |
NCT03000712 -
Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC Comared to Negative Control After High Tibial Osteotomy in the Osteoarthritis Patients.
|
N/A | |
Withdrawn |
NCT04057885 -
To Determine the Gait and Functional Improvement in Total Knee Arthroplasty
|
N/A | |
Completed |
NCT04815070 -
Gastric Volume in Diabetic Patients Undergoing Staged Bilateral Total Knee Arthroplasty
|
||
Active, not recruiting |
NCT02038140 -
Zimmer Trabecular Metal Total Ankle PMCF
|
N/A | |
Recruiting |
NCT02469662 -
Clinical Outcomes Study of the Nexel Total Elbow
|
N/A | |
Terminated |
NCT00588887 -
Total Knee Replacement With Duracon® and Vanguardâ„¢ Prostheses
|
N/A | |
Completed |
NCT03990805 -
A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis
|
Phase 3 | |
Completed |
NCT02658344 -
Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis
|
Phase 2 | |
Not yet recruiting |
NCT04821102 -
Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration
|
N/A | |
Terminated |
NCT02405234 -
Ascension PyroCarbon Radial Head Study
|
N/A |